Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 7Lung Neoplasms 5Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 2Colorectal Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Relapsed Pediatric Solid Tumor 1Rare Tumor 1Neurofibromatosis 2 1Lymphoma, Follicular 1Lung Adenocarcinoma Metastatic 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Castration-resistant Prostate Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Lobular 1Breast Neoplasms 1Advanced Cancers 1

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Endometrial Cancer Recurrent × Crizotinib × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡